HanchorBio Partners with WuXi Biologics to Accelerate Next-Generation Fusion Protein Development
Key Insights
HanchorBio (search) and WuXi Biologics announced a strategic collaboration to advance HanchorBio's bi- and multi-functional fusion protein pipeline using integrated development and manufacturing services.
The partnership leverages WuXi Biologics' expertise in complex biologics, supporting 945 projects with approximately 60% involving bi- and multi-specific antibodies, ADCs, and fusion proteins (search).
HanchorBio (search)'s proprietary FBDB™ platform enables rational design of multi-functional fusion proteins (search) targeting both innate and adaptive immunity for oncology (search) and autoimmune diseases (search).
HanchorBio (search), Inc. (TPEx: 7827), a global clinical-stage biotechnology company, has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK) to accelerate the development and manufacturing of next-generation bi- and multi-functional fusion proteins (search). The partnership aims to leverage WuXi Biologics' integrated Contract Research, Development, and Manufacturing Organization (CRDMO) capabilities to support HanchorBio's innovative immunotherapy pipeline.
Comprehensive Development and Manufacturing Support
Under the collaboration agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The partnership is designed to accelerate clinical translation, enhance Chemistry, Manufacturing, and Controls (CMC) execution efficiency, and support scalable global development of HanchorBio (search)'s fusion protein portfolio derived from its Fc (search)-Based Designer Biologics (FBDB™) platform.
The collaboration reflects HanchorBio (search)'s strategy to advance its platform-derived, multi-asset pipelines with enhanced development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities in complex biologics and global quality systems, HanchorBio aims to shorten development timelines while maintaining flexibility across multiple clinical programs.
WuXi Biologics' Complex Modality Expertise
WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (search) (ADCs), and fusion proteins (search). As of 2025, WuXi Biologics' integrated platform supports 945 projects, with approximately 60% involving bi- and multi-specific antibodies, ADCs, and fusion proteins, demonstrating its strong track record in accelerating the development and manufacturing of advanced therapeutic modalities.
The company's proprietary technology platforms, including the WuXia™ TrueSite targeted integration (TI)-based CHO cell line platform and WuXiHigh™ high-throughput formulation development platform, are designed to enhance speed, quality, and scalability. Bispecific and multispecific antibodies (search) represent WuXi Biologics' most exciting, fastest-growing, and highest-margin modality, contributing nearly 20% of the company's revenue and achieving year-over-year growth exceeding 120%.
HanchorBio's FBDB™ Platform Innovation
For HanchorBio (search), the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins (search) intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology (search) and autoimmune pipelines toward global clinical development.
The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models and enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome current challenges of anti-PD1 (search)/L1 immunotherapies.
Leadership Perspectives
Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio (search), commented: "This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline."
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: "We are excited to embark on this collaboration with HanchorBio (search), which underscores the strong trust they placed in WuXi Biologics' comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio's innovative bi-/multi fusion proteins (search) and help bring transformative therapies to patients worldwide."
Strategic Positioning for Global Development
The partnership positions both companies to capitalize on the growing demand for complex biologics. WuXi Biologics added 209 new integrated projects in 2025, with approximately 50% originating from U.S. clients, and maintains a pipeline of 196 bispecific/multispecific antibody projects and 252 ADC projects. The collaboration enables HanchorBio (search) to access WuXi Biologics' global manufacturing network and quality systems while focusing on advancing its innovative fusion protein programs designed to address significant unmet medical needs in oncology (search) and autoimmune diseases (search).